Comparative Pharmacology
Head-to-head clinical analysis: PLENDIL versus TIAZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENDIL versus TIAZAC.
PLENDIL vs TIAZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
Oral: 120-360 mg once daily; maximum 540 mg daily.
None Documented
None Documented
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker